Crystal structures of MKK4 kinase domain reveal that substrate peptide binds to an allosteric site and induces an auto-inhibition state

Biochemical and Biophysical Research Communications

Volumn 400, Issue 3, 2010, Pages 369-373

  Matsumoto, Takashi ^a,b   Kinoshita, Takayoshi ^b   Kirii, Yasuyuki ^c   Yokota, Koichi ^c   Hamada, Kensaku ^a   Tada, Toshiji ^b  

^a PharmAxess Inc   (Japan)

^b Osaka City University   (Japan)

^c 1 5 5 Minatojima Minamimachi   (Japan)

Author keywords

Activation helix; Allosteric binding; MAP kinase kinase; MKK4; X ray crystal structure

Indexed keywords

ADENYLYLIMIDODIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; SYNAPTOPHYSIN; ADENOSINE PHOSPHATE; MAP2K4 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDE;

ALLOSTERISM; ALPHA HELIX; ARTICLE; BINDING SITE; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; HUMAN; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

ADENOSINE MONOPHOSPHATE; ALLOSTERIC REGULATION; ALLOSTERIC SITE; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HUMANS; MAP KINASE KINASE 4; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY;

EID: 77956896283     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.071     Document Type: Article

References (23)

1. Dérijard B., Raingeaud J., Barrett T., Wu I.H., Han J., Ulevitch R.J., Davis R.J. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995, 267:682-685.
2. Lin A., Minden A., Martinetto H., Claret F.X., Lange-Carter C., Mercurio F., Johnson G.L., Karin M. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 1995, 268:286-290.
3. Widmann C., Gibson S., Jarpe M.B., Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 1999, 79:143-180.
4. Boulton T.G., Nye S.H., Robbins D.J., Ip N.Y., Radziejewska E., Morgenbesser S.D., DePinho R.A., Panayotatos N., Cobb M.H., Yancopoulos G.D. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991, 65:663-675.
5. Wang X., Destrument A., Tournier C. Physiological roles of MKK4 and MKK7: insights from animal models. Biochim. Biophys. Acta 2007, 1773:1349-1357.
6. Brancho D., Tanaka N., Jaeschke A., Ventura J.J., Kelkar N., Tanaka Y., Kyuuma M., Takeshita T., Flavell R.A., Davis R.J. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003, 17:1969-1978.
7. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2003, 103:239-252.
8. Cuenda A. Mitogen-activated protein kinase kinase 4 (MKK4). Int. J. Biochem. Cell Biol. 2000, 32:581-587.
9. Robinson V.L., Hickson J.A., Vander Griend D.J., Dubauskas Z., Rinker-Schaeffer C.W. MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research. Clin. Exp. Metastasis 2003, 20:25-30.
10. Kim H.L., Vander Griend D.J., Yang X., Benson D.A., Dubauskas Z., Yoshida B.A., Chekmareva M.A., Ichikawa Y., Sokoloff M.H., Zhan P., Karrison T., Lin A., Stadler W.M., Ichikawa T., Rubin M.A., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res. 2001, 61:2833-2837.
11. Yamada S.D., Hickson J.A., Hrobowski Y., Vander Griend D.J., Benson D., Montag A., Karrison T., Huo D., Rutgers J., Adams S., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 2002, 62:6717-6723.
12. Robbins D.J., Zhen E., Owaki H., Vanderblit C.A., Ebert D., Geppert T.D., Cobb M.H. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vivo. J. Biol. Chem. 1993, 268:5097-5106.
13. Kinoshita T., Miyano N., Nakai R., Yokota K., Ishiguro H., Tada T. Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase. Protein Expr. Purif. 2008, 58:318-324.
14. Collaborative Computational Project, Number 4, The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D50 (1994) 760-763.
15. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
16. Vagin A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30:1022-1025.
17. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. 2004, D60:2126-2132.
18. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. 1997, D53:240-255.
19. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., Moriarty N.W., Read R.J., Sacchettini J.C., Sauter N.K., Terwilliger T.C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. 2002, D58:1948-1954.
20. Krissinel E., Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. 2004, D60:2256-2268.
21. Potterton L., McNicholas S., Krissinel E., Gruber J., Cowtan K., Emsley P., Murshudov G.N., Cohen S., Perrakis A., Noble M. Developments in the CCP4 molecular-graphics project. Acta Crystallogr. 2004, D60:2288-2294.
22. Fischmann T.O., Smith C.K., Mayhood T.W., Myers J.E., Reichert P., Mannarino A., Carr D., Zhu H., Wong J., Yang R.S., Le H.V., Madison V.S. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 2009, 31:2661-2674.
23. Iverson C., Larson G., Lai C., Yeh L.T., Dadson C., Weingarten P., Appleby T., Vo A., Maderna A., Vernier J.M., Hamatake R., Miner J.N., Quart B. RDEA119/BAY869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009, 69:6839-6847.